Trial name or title	Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Liposomal Doxorubicin in BRCA positive Advanced Ovarian Cancer (ICEBERG 3)
Methods	Phase II, Randomised,Open-Label, Comparative, International Multicenter Study
Participants	Advanced ovarian cancer with positive BRCA1 or BRCA2 status Progressive or recurrent disease after platinum-based chemotherapy
Interventions	Experimental arm: AZD2281 given at 400 mg twice daily AZD2281 given at 200 mg twice daily Active comparator arm: Liposomal Doxorubicin (LPD) 50mg/m2 intravenously every 4 weeks
Outcomes	Primary Efficacity measured by Progression-free survival (PFS) Best overall response (ORR) Duration of response Cancer antigen (CA)-125 response measured every 4 weeks Radiological tumour assessments will be performed every 12 weeks for 1st 60 weeks and then every 24 weeks Secondary Comparison of safety and tolerability
Starting date	July 2008
Contact information	Information.Center@astrazeneca.com
Notes	http://clinicaltrials.gov/show/NCT00628251